Gossamer Bio director receives 115K stock options

Gossamer Bio, Inc. director Sandra Milligan received a grant of stock options covering 115,000 shares of common stock.

Rhea-AI Filing Summary

Gossamer Bio, Inc. director Sandra Milligan received a grant of stock options covering 115,000 shares of common stock. The options have an exercise price of $0.178 per share and expire on June 3, 2036. The award was made under the company’s Non-Employee Director Compensation Program and becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to her continued board service. Following this grant, she holds 115,000 stock options directly.

Insider Trade Summary

Grant/Award: 115,000 shares

Grant/Award 1 txn

Insider Milligan Sandra

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	115,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 115,000 contracts (Direct)

Footnotes (2)

1. F1. Award made pursuant to Non-Employee Director Compensation Program.
2. F2. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Key Figures

Option grant size: 115,000 options Exercise price: $0.178 per share Expiration date: June 3, 2036 +2 more

5 metrics

Option grant size 115,000 options Stock Option (Right to Buy) awarded to director

Exercise price $0.178 per share Conversion or exercise price of option grant

Expiration date June 3, 2036 Option expiration for director grant

Underlying shares 115,000 shares Common stock underlying the options

Post-grant holdings 115,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), Non-Employee Director Compensation Program, exercise price, vested and exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Non-Employee Director Compensation Program financial

"Award made pursuant to Non-Employee Director Compensation Program."

exercise price financial

"conversion_or_exercise_price: 0.1780"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested and exercisable financial

"becomes fully vested and exercisable on the first to occur"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Gossamer Bio (GOSS) director Sandra Milligan report on this Form 4?

Sandra Milligan reported receiving a grant of stock options for 115,000 shares of Gossamer Bio common stock. These options were issued as director compensation and are not an open-market purchase or sale of existing shares.

What are the key terms of Sandra Milligan’s Gossamer Bio stock options?

The options cover 115,000 shares of common stock at an exercise price of $0.178 per share. They expire on June 3, 2036, giving a long-dated right to buy shares at that fixed price if vested.

How and when do Sandra Milligan’s Gossamer Bio options vest?

The entire 115,000-share option grant vests and becomes exercisable on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Vesting is conditioned on her continued service on Gossamer Bio’s board through that date.

Is Sandra Milligan buying or selling Gossamer Bio (GOSS) stock in this filing?

The filing reflects an option grant as compensation, not a stock trade. She acquired a right to buy 115,000 shares in the future at $0.178 per share, rather than purchasing or selling shares in the open market.

How many Gossamer Bio options does Sandra Milligan hold after this grant?

After this transaction, Sandra Milligan holds stock options on 115,000 shares directly. This entire position comes from the newly granted award reported in the Form 4 and reflects her current option holdings in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:28 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milligan Sandra

(Last) (First) (Middle)

3115 MERRYFIELD ROW, SUITE 120

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.178	06/04/2026		A		115,000(1)		(2)	06/03/2036	Common Stock	115,000	$0	115,000	D

Explanation of Responses:

1. Award made pursuant to Non-Employee Director Compensation Program.

2. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Remarks:

	/s/ Christian Waage, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)